This statement constitutes Amendment No. 1 to the Schedule 13D relating to the Common Stock, par value $0.001 (the “Shares”), issued by ARIAD Pharmaceuticals, Inc. (the “Issuer”), and hereby amends the Schedule 13D filed with the Securities and Exchange Commission on October 29, 2013 (the "Initial Schedule 13D"), on behalf of the Reporting Persons (as defined in the Initial Schedule 13D), to furnish the additional information set forth herein. All capitalized terms contained herein but not otherwise defined shall have the meanings ascribed to such terms in the Initial Schedule 13D.
Item 3. Source or Amount of Funds or Other Consideration.
Item 3 of the Initial Schedule 13D is hereby amended by replacing it in its entirety with the following:
The Reporting Persons may be deemed to be the beneficial owner of, in the aggregate, 12,000,000 Shares. The aggregate purchase price of the Shares purchased by the Reporting Persons collectively was approximately $45 million (including commissions). The source of funding for these Shares was the general working capital of the respective purchasers.
Item 4. Purpose of Transaction.
Item 4 of the Initial Schedule 13D is hereby amended by adding the following:
On February 20, 2014, the Reporting Persons entered into an agreement with the Issuer (the “
Nomination Agreement
”) pursuant to which the Issuer agreed to immediately appoint Alexander Denner to the Issuer’s board and to subsequently appoint an additional director to the board approved by Alexander Denner.
In connection with the Nomination Agreement, the Reporting Persons also entered into a confidentiality agreement with the Issuer (“Confidentiality Agreement”). Copies of the Nomination Agreement and Confidentiality Agreement are filed herewith as exhibits and incorporated herein by reference, and any description herein of the Nomination Agreement or the Confidentiality Agreement is qualified in its entirety by reference to the Nomination Agreement and Confidentiality Agreement filed herewith.
Item 5. Interest in Securities of the Issuer.
Items 5 (a) and (b) of the Initial Schedule 13D are hereby amended by replacing them in their entirety with the following:
(a) The Reporting Persons may be deemed to beneficially own, in the aggregate, 12,000,000 Shares representing approximately 6.46% of the Issuer's outstanding Shares (based upon the 185,656,233 Shares stated to be outstanding as of October 31, 2013 by the Issuer in the Issuer’s Form 10−Q for the quarterly period ended September 30, 2013).
(b) For purposes of this Schedule 13D:
Sarissa Domestic has sole voting power and sole dispositive power with regard to 7,183,199 Shares. Sarissa Offshore has sole voting power and sole dispositive power with regard to 4,816,801 Shares. Sarissa Capital, as the investment advisor to the Sarissa Funds, may be deemed to have the shared power to vote or direct the vote of (and the shared power to dispose or direct the disposition of) the 12,000,000 Shares held by the Sarissa Funds. By virtue of his position as the Chief Investment Officer of Sarissa Capital and as the managing member of Sarissa Capital’s general partner and as controlling the ultimate general partner of each of the Sarissa Funds, Dr. Denner may be deemed to have the shared power to vote or direct the vote of (and the shared power to dispose or direct the disposition of) the 12,000,000 Shares held by the Sarissa Funds.